GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date

References

• Davidson JA. The increasing role of primary care physicians in caring for patients with type 2 diabetes mellitus. Mayo Clin Proc. 2010;85(12 Suppl):S3–S4.
   PubMedGoogle Scholar
• Shrivastav M, Gibson W Jr, Shrivastav R, et al. Type 2 diabetes management in primary care: the role of retrospective, professional continuous glucose monitoring. Diabetes Spectr. 2018;31(3):279–287.
   PubMedGoogle Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98–S110.
   PubMed Web of Science ®Google Scholar
• Carls G, Huynh J, Tuttle E, et al. Achievement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Ther. 2017;8(4):863–873.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 6. Glycemic targets: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S66–S76.
   PubMed Web of Science ®Google Scholar
• Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411–3417.
   PubMed Web of Science ®Google Scholar
• Santos Cavaiola T, Kiriakov Y, Reid T. Primary care management of patients with type 2 diabetes: overcoming inertia and advancing therapy with the use of injectables. Clin Ther. 2019;41(2):352–367.
   PubMed Web of Science ®Google Scholar
• Aroda VR. A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials. Diabetes Obes Metab. 2018;20(Suppl 1):22–33.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Davies MJ, Khunti K. What have we learnt from “real world” data, observational studies and meta-analyses. Diabetes Obes Metab. 2018;20(Suppl 1):47–58.
   PubMed Web of Science ®Google Scholar
• Levin PA, Nguyen H, Wittbrodt ET, et al. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes Metab Syndr Obes. 2017;10:123–139.
   PubMed Web of Science ®Google Scholar
• Ozempic^® (semaglutide) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209637s003lbl.pdf
   Google Scholar
• Trulicity^® (dulaglutide) prescribing information [updated Feb 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s033lbl.pdf
   Google Scholar
• Victoza® (liraglutide) prescribing information [updated Jun 2019; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022341s031lbl.pdf
   Google Scholar
• DeFronzo RA, Triplitt CL, Abdul-Ghani M, et al. Novel agents for the treatment of type 2 diabetes. Diabetes Spectr. 2014;27(2):100–112.
   PubMedGoogle Scholar
• DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019.
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–2157.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Habener JF, Holst JJ. Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest. 2017;127(12):4217–4227.
   PubMed Web of Science ®Google Scholar
• Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409–1439.
   PubMed Web of Science ®Google Scholar
• Holst JJ, Knop FK, Vilsbøll T, et al. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care. 2011;34(Suppl 2):S251–S257.
   PubMed Web of Science ®Google Scholar
• Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016;18(3):203–216.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani M, DeFronzo RA. Is it time to change the type 2 diabetes treatment paradigm? Yes! GLP-1 RAs should replace metformin in the type 2 diabetes algorithm. Diabetes Care. 2017;40(8):1121–1127.
   PubMed Web of Science ®Google Scholar
• Gentilella R, Pechtner V, Corcos A, et al. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? Diabetes Metab Res Rev. 2019;35(1):e3070.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ, Cavender MA, et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136:849–870.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ. Are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181:R211–R234.
   PubMed Web of Science ®Google Scholar
• Ryan D, Acosta A. GLP-1 receptor agonists: nonglycemic clinical effects in weight loss and beyond. Obesity (Silver Spring). 2015;23(6):1119–1129.
   PubMed Web of Science ®Google Scholar
• Byetta^® (exenatide) prescribing information [updated Feb 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021773s043lbl.pdf
   Google Scholar
• Bydureon^® (exenatide extended-release) prescribing information [updated Feb 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022200s030lbl.pdf
   Google Scholar
• Bydureon BCise^® (exenatide extended-release) prescribing information [updated Feb 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209210s011lbl.pdf
   Google Scholar
• Adlyxin^® (lixisenatide) prescribing information [updated Jan 2019; cited 2020 May 25]. Available from: http://products.sanofi.us/Adlyxin/Adlyxin.pdf
   Google Scholar
• Xultophy^® (liraglutide + insulin degludec) prescribing information [updated Nov 2019; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208583s014s015lbl.pdf
   Google Scholar
• Soliqua^® (lixisenatide + insulin glargine) prescribing information [updated Nov 2019; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208673s008s009lbl.pdf
   Google Scholar
• Rybelsus^® (semaglutide) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213182s000,213051s001lbl.pdf
   Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728–742.
   PubMed Web of Science ®Google Scholar
• US Food & Drug Administration. FDA approves first oral GLP-1 treatment for type 2 diabetes, 2019 [cited 2020 May 25]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes
   Google Scholar
• Clinicaltrials.gov. A heart disease study of semaglutide in patients with type 2 diabetes (SOUL). ClinicalTrials.gov Identifier: NCT03914326 [cited 2020 May 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03914326
   Google Scholar
• Lyseng-Williamson KA. Glucagon-like peptide-1 receptor analogues in type 2 diabetes: their use and differential features. Clin Drug Investig. 2019;39(8):805–819.
   PubMed Web of Science ®Google Scholar
• Lingvay I, Catarig A-M, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834–844.
   PubMed Web of Science ®Google Scholar
• Ankarfeldt MZ, Adalsteinsson E, Groenwold RH, et al. A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs. Clin Epidemiol. 2017;9:41–51.
   PubMed Web of Science ®Google Scholar
• Feher M, Vega-Hernandez G, Mocevic E, et al. Effectiveness of liraglutide and lixisenatide in the treatment of type 2 diabetes: real-world evidence from The Health Improvement Network (THIN) database in the United Kingdom. Diabetes Ther. 2017;8(2):417–431.
   PubMed Web of Science ®Google Scholar
• Martinez L, Penfornis A, Gautier JF, et al. Effectiveness and persistence of liraglutide treatment among patients with type 2 diabetes treated in primary care and specialist settings: a subgroup analysis from the EVIDENCE study, a prospective, 2-year follow-up, observational, post-marketing study. Adv Ther. 2017;34(3):674–685.
   PubMed Web of Science ®Google Scholar
• Mata-Cases M, Franch-Nadal J, Ortega E, et al. Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: real-world evidence from a Mediterranean area. Curr Med Res Opin. 2019;35(10):1735–1744.
   PubMed Web of Science ®Google Scholar
• Moreno Obregón F, Miramontes-González JP, Romo Guajardo-Fajardo C, et al. Real-life experience with dulaglutide: analysis of clinical effectiveness to 24 months. Diabetes Res Clin Pract. 2019;158:107916.
   PubMed Web of Science ®Google Scholar
• Nyeland ME, Ploug UJ, Richards A, et al. Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care. Int J Clin Pract. 2015;69(3):281–291.
   PubMed Web of Science ®Google Scholar
• Ostawal A, Mocevic E, Kragh N, et al. Clinical effectiveness of liraglutide in type 2 diabetes treatment in the real-world setting: a systematic literature review. Diabetes Ther. 2016;7(3):411–438.
   PubMed Web of Science ®Google Scholar
• Philis-Tsimikas A, Wysham CH, Hardy E, et al. Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: an open-label extension of the DURATION-1 study. J Diabetes Complications. 2019;33(3):223–230.
   PubMed Web of Science ®Google Scholar
• Tran S, Retnakaran R, Zinman B, et al. Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2018;20(Suppl 1):68–76.
   PubMed Web of Science ®Google Scholar
• Hussein H, Zaccardi F, Khunti K, et al. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. Diabetes Obes Metab. 2020;22:1035–1046.
   PubMed Web of Science ®Google Scholar
• Castellana M, Cignarelli A, Brescia F, et al. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: a meta-analysis. Sci Rep. 2019;9(1):19351.
   PubMed Web of Science ®Google Scholar
• Guo M, Gu J, Teng F, et al. The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis. Endocrine. 2020;67(2):294–304.
   PubMed Web of Science ®Google Scholar
• Abd El Aziz MS, Kahle M, Meier JJ, et al. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab. 2017;19(2):216–227.
   PubMed Web of Science ®Google Scholar
• Singh S, Wright EE Jr, Kwan AY, et al. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2017;19(2):228–238.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–286.
   PubMed Web of Science ®Google Scholar
• Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258–266.
   PubMed Web of Science ®Google Scholar
• Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100–109.
   Web of Science ®Google Scholar
• Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301–1310.
   PubMed Web of Science ®Google Scholar
• Witkowski M, Wilkinson L, Webb N, et al. A systematic literature review and network meta-analysis comparing once-weekly semaglutide with other GLP-1 receptor agonists in patients with type 2 diabetes previously receiving 1-2 oral anti-diabetic drugs. Diabetes Ther. 2018;9(3):1149–1167.
   PubMed Web of Science ®Google Scholar
• Maiorino MI, Chiodini P, Bellastella G, et al. The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2019;154:101–115.
   PubMed Web of Science ®Google Scholar
• Castellana M, Cignarelli A, Brescia F, et al. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2019;35(1):e3082.
   PubMed Web of Science ®Google Scholar
• Wysham CH, Lin J, Kuritzky L. Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis. Postgrad Med. 2017;129(4):436–445.
   PubMed Web of Science ®Google Scholar
• US Food & Drug Administration. Guidance document: diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, 2008 [cited 2020 May 25]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diabetes-mellitus-evaluating-cardiovascular-risk-new-antidiabetic-therapies-treat-type-2-diabetes
   Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130.
   PubMed Web of Science ®Google Scholar
• Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–1239.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
   PubMed Web of Science ®Google Scholar
• Hinnen D, Kruger DF. Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials. Diabetes Metab Syndr Obes. 2019;12:447–455.
   PubMed Web of Science ®Google Scholar
• Reid TS. Practical use of glucagon-like peptide-1 receptor agonist therapy in primary care. Clin Diabetes. 2013;31(4):148–157.
   Google Scholar
• Milne N. How to use GLP-1 receptor agonist therapy safely and effectively. Diabet Prim Care. 2019;21:45–46.
   Google Scholar
• Abd El Aziz M, Cahyadi O, Meier JJ, et al. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab. 2020;22:699–704.
   PubMed Web of Science ®Google Scholar
• Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283.
   PubMedGoogle Scholar
• Azoulay L, Filion KB, Platt RW, et al. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ. 2016;352:i581.
   PubMed Web of Science ®Google Scholar
• Boniol M, Franchi M, Bota M, et al. Incretin-based therapies and the short-term risk of pancreatic cancer: results from two retrospective cohort studies. Diabetes Care. 2018;41(2):286–292.
   PubMed Web of Science ®Google Scholar
• Pinto LC, Falcetta MR, Rados DV, et al. Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis. Sci Rep. 2019;9(1):2375.
   PubMed Web of Science ®Google Scholar
• Byetta^® (exenatide) Summary of Product Characteristics [updated Mar 2020; cited 2020 May 25]. Available from: https://www.ema.europa.eu/en/documents/product-information/byetta-epar-product-information_en.pdf
   Google Scholar
• Bydureon^® (exenatide extended-release) Summary of Product Characteristics [updated Feb 2020; cited 2020 May 25]. Available from: https://www.ema.europa.eu/en/documents/product-information/bydureon-epar-product-information_en.pdf
   Google Scholar
• Lyxumia^® (lixisenatide) Summary of Product Characteristics [updated Mar 2020; cited 2020 May 25]. Available from: https://www.ema.europa.eu/en/documents/product-information/lyxumia-epar-product-information_en.pdf
   Google Scholar
• Ozempic^® (semaglutide) Summary of Product Characteristics [updated Apr 2020; cited 2020 May 25]. Available from: https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf
   Google Scholar
• Trulicity^® (dulaglutide) Summary of Product Characteristics [updated Nov 2019; cited 2020 May 25]. Available from: https://www.ema.europa.eu/en/documents/product-information/trulicity-epar-product-information_en.pdf
   Google Scholar
• Victoza^® (liraglutide) Summary of Product Characteristics [updated Nov 2019; cited 2020 May 25]. Available from: https://www.ema.europa.eu/en/documents/product-information/victoza-epar-product-information_en.pdf
   Google Scholar
• Brunton SA, Mosenzon O, Wright EE. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how? Postgrad Med. 2020;132(S2):48–60.
   Google Scholar
• Bain SC, Klufas MA, Ho A, et al. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review. Diabetes Obes Metab. 2019;21(3):454–466.
   PubMed Web of Science ®Google Scholar
• Avgerinos I, Karagiannis T, Malandris K, et al. Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(1):188–193.
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889–897.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019;45(5):409–418.
   PubMed Web of Science ®Google Scholar
• Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341–354.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–366.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291–2301.
   PubMed Web of Science ®Google Scholar
• Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–260.
   PubMed Web of Science ®Google Scholar
• Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356–367.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 11. Microvascular complications and foot care: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S135–S151.
   PubMed Web of Science ®Google Scholar
• Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69–77.
   PubMed Web of Science ®Google Scholar
• Tougaard RS, Jorsal A, Tarnow L, et al. Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events [published online ahead of print, 2020 Apr 15]. Scand Cardiovasc J. 2020;1–6.
   Google Scholar
• Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–785.
   PubMed Web of Science ®Google Scholar
• Buysman EK, Liu F, Hammer M, et al. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study. Adv Ther. 2015;32(4):341–355.
   PubMed Web of Science ®Google Scholar
• Mody R, Grabner M, Yu M, et al. Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment. Curr Med Res Opin. 2018;34(6):995–1003.
   PubMed Web of Science ®Google Scholar
• Nguyen H, Dufour R, Caldwell-Tarr A. Glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy adherence for patients with type 2 diabetes in a Medicare population. Adv Ther. 2017;34(3):658–673.
   PubMed Web of Science ®Google Scholar
• Giorgino F, Penfornis A, Pechtner V, et al. Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement. Patient Prefer Adherence. 2018;12:707–719.
   PubMed Web of Science ®Google Scholar
• Alatorre C, Fernández Landó L, Yu M, et al. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide. Diabetes Obes Metab. 2017;19(7):953–961.
   PubMed Web of Science ®Google Scholar
• Johnston SS, Nguyen H, Felber E, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther. 2014;31(11):1119–1133.
   PubMed Web of Science ®Google Scholar
• Lemstra M, Nwankwo C, Bird Y, et al. Primary nonadherence to chronic disease medications: a meta-analysis. Patient Prefer Adherence. 2018;12:721–731.
   PubMed Web of Science ®Google Scholar
• Hamersky CM, Fridman M, Gamble CL, et al. Injectable antihyperglycemics: a systematic review and critical analysis of the literature on adherence, persistence, and health outcomes. Diabetes Ther. 2019;10(3):865–890.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.
   PubMed Web of Science ®Google Scholar
• Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care. 2019;42(3):416–426.
   PubMed Web of Science ®Google Scholar
• Paul SK, Klein K, Thorsted BL, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100.
   PubMed Web of Science ®Google Scholar
• Thieu VT, Robinson S, Kennedy-Martin T, et al. Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes. Patient Prefer Adherence. 2019;13:561–576.
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299–1307.
   PubMed Web of Science ®Google Scholar
• Okemah J, Peng J, Quiñones M. Addressing clinical inertia in type 2 diabetes mellitus: a review. Adv Ther. 2018;35:1735–1745.
   PubMed Web of Science ®Google Scholar
• Bui V, Neumiller JJ. Oral semaglutide. Clin Diabetes. 2018;36(4):327–329.
   PubMedGoogle Scholar
• Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047.
   PubMed Web of Science ®Google Scholar
• Renukuntla J, Vadlapudi AD, Patel A, et al. Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm. 2013;447:75–93.
   PubMed Web of Science ®Google Scholar
• Granhall C, Donsmark M, Blicher TM, et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clin Pharmacokinet. 2019;58(6):781–791.
   PubMed Web of Science ®Google Scholar
• Novo Nordisk. Rybelsus^® approved in Japan for the treatment of type 2 diabetes, 2020 [cited 2020 Jul 7]. Available from: https://www.novonordisk.com/media/news-details.2325697.html
   Google Scholar
• Rybelsus^® product monograph including patient medication information; date of initial approval: March 30, 2020 [cited 2020 Jun 24]. Available from: https://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/Rybelsus-PM-EN-monograph.pdf
   Google Scholar
• Rybelsus^® Summary of Product Characteristics [updated Jun 2020; cited 2020 Jun 24]. Available from: https://www.ema.europa.eu/en/documents/product-information/rybelsus-epar-product-information_en.pdf
   Google Scholar
• Rybelsus^® Swiss public assessment report; decision date: 24 March 2020 [cited 2020 Jun 24]. Available from: https://www.swissmedic.ch/dam/swissmedic/de/dokumente/zulassung/swisspar/67446-rybelsus-01-swisspar-20200430.pdf.download.pdf/SwissPAR_Rybelsus_final.pdf
   Google Scholar
• Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724–1732.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272–2281.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466–1480.
   PubMed Web of Science ®Google Scholar
• Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39–50.
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515–527.
   PubMed Web of Science ®Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–851.
   PubMed Web of Science ®Google Scholar
• Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528–539.
   PubMed Web of Science ®Google Scholar
• Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42(12):2262–2271.
   PubMed Web of Science ®Google Scholar
• Yabe D, Nakamura J, Kaneto H, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2020;8:392–406.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Katagiri H, Hamamoto Y, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. Lancet Diabetes Endocrinol. 2020;8:377–391.
   PubMed Web of Science ®Google Scholar